CSAPG-37NCT05920382
Radiofrequency Ablation for the Treatment of Post-knee Arthroplasty Chronic Pain.
At risk: Primary completion moved 12 months later.
See at-risk trials from Consorci Sanitari de l'Alt Penedès i Garraf
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 1, 2026 to Sep 1, 2027 Show 5 more changesShow less
- Eligibility criteria expanded, about 10 words
- Study completion pushed from Dec 1, 2027 to Dec 1, 2028
- Secondary endpoints: details revised at 3 of 7 entries
- Site details revised
- Publications: details revised at 1 of 1 entry
- Notable Primary completion date: Sep 1, 2025 to Sep 1, 2026
- Start date: Sep 29, 2023 to Sep 25, 2023
- Publications: 15 to 1
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Sep 15, 2023 to Sep 29, 2023
- Minor Secondary endpoints: 6 to 7v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
After identifying the nerves to be treated via ultrasound and confirming with neurostimulation, 1 ml of 2% lidocaine will be administered, followed by radiofrequency ablation. The physical parameters used are as follows: 90 seconds, 80 degrees Celsius, with a 22g needle with an active tip of 10 mm.
In the same manner as with the RF group, the nerves to be treated are identified via ultrasound and confirmed by neurostimulation. Subsequently, sham radiofrequency is performed for 90 seconds.
Procedures: Radiofrequency ablation of peripheral nerves.
Sites
1 site in 1 country
- Consorci Sanitari Alt'Pènedes i GarrafBarcelona, Catalonia, Spain